Literature DB >> 7522962

Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis.

M F Press1, M C Pike, G Hung, J Y Zhou, Y Ma, J George, J Dietz-Band, W James, D J Slamon, J G Batsakis.   

Abstract

There are few reliable prognostic markers of biological aggressiveness for head and neck carcinomas in general. For salivary gland carcinomas, anatomic location, tumor size, histological grade, and extent of disease involvement are considered to be clinically important risk factors for recurrent disease. Molecular genetic alterations in salivary gland carcinomas have not been characterized, and tumor cell proteins have not been shown to be prognostically significant. Here a cohort of mucoepidermoid carcinomas of the major (parotid and submandibular) salivary glands are analyzed for a molecular genetic alteration, HER-2/neu gene amplification, and gene amplification and expression results are compared with long-term clinical follow-up information. Archival tissues resected from 58 patients with mucoepidermoid carcinoma of salivary glands were evaluated for HER-2/neu gene amplification by fluorescence in situ hybridization and for gene expression by immunohistochemistry in a blinded fashion. Clinical follow-up information was compared with the results of these analyses to determine whether there were significant associations. Overexpression, identified as membrane immunostaining by immunohistochemistry, was observed in 22 of 58 (38%) mucoepidermoid carcinomas. Gene amplification, characterized by fluorescence in situ hybridization, was observed in 12 (21%) cases. Eleven of the 12 cases with gene amplification were also immunostained for HER-2/neu. Both gene amplification (P = 0.0001, P < 0.0001) and immunostaining (P < 0.0001, P < 0.0001) were correlated with shorter disease-free interval and poorer overall patient survival, respectively. Multivariate analysis showed that HER-2/neu immunostaining and amplification were markers of poor prognosis independent of histopathological grade, tumor size, and involvement of regional lymph nodes. HER-2/neu is amplified and/or overexpressed in approximately one-third of mucoepidermoid carcinomas of salivary glands. Amplification and/or overexpression appears to be an independent marker of poor prognosis in mucoepidermoid carcinomas of the salivary glands as it is in carcinomas of the breast, ovary, and endometrium.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522962

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  The Role of Human Epidermal Growth Factor Receptor 2 (HER2/neu) in Mucoepidermoid Carcinomas.

Authors:  Shirin Saravani
Journal:  J Clin Diagn Res       Date:  2016-07-01

2.  Molecular modeling of nearly full-length ErbB2 receptor.

Authors:  Péter Bagossi; Gábor Horváth; György Vereb; János Szöllösi; József Tözsér
Journal:  Biophys J       Date:  2004-12-13       Impact factor: 4.033

3.  Immunoexpression of c-erbB-2 and p53 in benign and malignant salivary neoplasms with myoepithelial differentiation.

Authors:  J C Rosa; A Félix; I Fonseca; J Soares
Journal:  J Clin Pathol       Date:  1997-08       Impact factor: 3.411

4.  Coexpression of p53 and c-erbB-2 proteins is associated with histological type, tumour stage, and cell proliferation in malignant salivary gland tumours.

Authors:  N Kamio
Journal:  Virchows Arch       Date:  1996-05       Impact factor: 4.064

5.  Management and outcome of salivary duct carcinoma in major salivary glands.

Authors:  Elina Salovaara; Olli Hakala; Leif Bäck; Petri Koivunen; Kauko Saarilahti; Fabricio Passador-Santos; Ilmo Leivo; Antti A Mäkitie
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-03-22       Impact factor: 2.503

Review 6.  Salivary mucoepidermoid carcinoma revisited.

Authors:  Andrés Coca-Pelaz; Juan P Rodrigo; Asterios Triantafyllou; Jennifer L Hunt; Alessandra Rinaldo; Primož Strojan; Missak Haigentz; William M Mendenhall; Robert P Takes; Vincent Vander Poorten; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-26       Impact factor: 2.503

7.  Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture.

Authors:  Ja Hye Myung; Michael J Eblan; Joseph M Caster; Sin-Jung Park; Michael J Poellmann; Kyle Wang; Kevin A Tam; Seth M Miller; Colette Shen; Ronald C Chen; Tian Zhang; Joel E Tepper; Bhishamjit S Chera; Andrew Z Wang; Seungpyo Hong
Journal:  Clin Cancer Res       Date:  2018-03-15       Impact factor: 12.531

8.  Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation.

Authors:  Adriana Handra-Luca; Hadi Bilal; Jacques-Charles Bertrand; Pierre Fouret
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

9.  Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.

Authors:  M A Gordon; H M Gundacker; J Benedetti; J S Macdonald; J C Baranda; W J Levin; C D Blanke; W Elatre; P Weng; J Y Zhou; H J Lenz; M F Press
Journal:  Ann Oncol       Date:  2013-03-22       Impact factor: 32.976

10.  Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.

Authors:  Wenhsiang Wen; Wangjuh Sting Chen; Nick Xiao; Ryan Bender; Anatole Ghazalpour; Zheng Tan; Jeffrey Swensen; Sherri Z Millis; Gargi Basu; Zoran Gatalica; Michael F Press
Journal:  J Mol Diagn       Date:  2015-09       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.